Average time Control-IQ study participants spent in closed loop over a six-month period.1
Percent of Control-IQ participants said the feature on the t:slim X2 insulin pump was easy to use.2
Average time in range per day spent by Control-IQ participants, versus 64% with sensor augmented pump.1
In a 12-month real-world study from the University of Virginia, sensor time in range for study participants increased from 63.6% at baseline to 73.6% after using the t:slim X2 insulin pump with Control-IQ technology. Glycemic improvement was observed in all age groups, was immediate after just two weeks of use, and continued for the entire 12-month period.1 This demonstrates the immediate and sustained benefits of Control-IQ technology for both children and adults.See the evidence
The t:slim X2 insulin pump can be used with or without continuous glucose monitoring (CGM).‡ For patients who use CGM, you can also prescribe either Control-IQ technology or Basal-IQ technology for automated insulin delivery.
Like all Tandem products, Control-IQ technology is easy to use, learn, and teach. Our predictive technologies integrate with your patients’ existing t:slim X2 insulin pump, so they don’t need to learn an entirely new system.
Through the t:connect HCP web application, you can upload, view, and print patient data from a single user-friendly webpage accessible from any internet-connected computer, anytime, anywhere in the United States.
The t:slim X2 insulin pump integrates with the Dexcom G6 CGM and does not require fingersticks for calibration or mealtime dosing.†
† If glucose alerts and Dexcom G6 CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
Review clinical study outcomes, compare product specs, and check out the reporting capabilities of t:connect HCP web application.
Find all the information you need to make prescribing easy for your practice and to help get your patients started on Tandem products.
*As measured by CGM.
† Zero fingersticks required when using the t:slim X2 pump with Dexcom G6 CGM integration. If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
‡ CGM sold separately.
1. Breton MD, Kovatchev BP. One year real-world use of the Control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021;23(9):601-608. doi: 10.1089/dia.2021.0097.
2. Brown S, et al. Clinical Acceptance of the Artificial Pancreas: The iDCL Trial. Poster presentation. 79th Scientific Sessions, American Diabetes Association, San Francisco, CA; June 9, 2019.
Important Safety Information
RX ONLY. The t:slim X2 insulin pump, Basal-IQ technology, and Control-IQ technology are intended for single patient use. The t:slim X2 pump, Basal-IQ technology, and Control-IQ technology are indicated for use with U-100 insulin only.
t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals six years of age and greater. Basal-IQ technology: Basal-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically suspend delivery of insulin based on iCGM readings and predicted glucose values. The bolus calculator is indicated for the management of diabetes by people with diabetes by calculating an insulin dose or carbohydrate intake based on user entered data. Basal-IQ technology is intended for the management of diabetes mellitus in persons six years of age and greater. Control-IQ technology: Control-IQ technology is intended for use with a compatible iCGM (sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons six years of age and greater.
|WARNING: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.|
Control-IQ technology and Basal-IQ technology are not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump, Basal-IQ technology, and Control-IQ technology must: be able and willing to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump, and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.